Related Experiment Video

Updated: Jul 14, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Emerging therapies for the treatment of patients with advanced neuroendocrine tumors

Jennifer A Chan1, Matthew H Kulke

  • 1Dana-Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA. jang@partners.org

Expert Opinion on Emerging Drugs
|July 3, 2007
PubMed

Insights

Treatment for neuroendocrine tumors lacks a standard approach. While somatostatin analogs manage symptoms, novel therapies like radiolabeled analogs and targeted agents show promise for advanced disease.

Area of Science:

  • Oncology
  • Endocrinology
  • Medical Therapeutics

Background:

  • Neuroendocrine tumors (NETs) present diverse treatment challenges with no single standard approach.
  • Current treatments like somatostatin analogs effectively manage hormonal hypersecretion but rarely induce tumor regression.
  • Systemic therapies, including chemotherapy and IFN-alpha, offer limited clinical benefit and potential toxicity in advanced NETs.

Purpose of the Study:

  • To review current treatment options for neuroendocrine tumors.
  • To highlight the limitations of existing therapies and the need for novel approaches.
  • To discuss emerging treatments, including targeted therapies and radiolabeled somatostatin analogs.

Main Methods:

  • Review of current literature on neuroendocrine tumor management.
  • Analysis of the efficacy and limitations of somatostatin analogs, surgery, chemotherapy, and IFN-alpha.
  • Exploration of novel therapeutic strategies, including radiolabeled somatostatin analogs, VEGF inhibitors, and mTOR inhibitors.

Main Results:

  • Somatostatin analogs are effective for symptom control but not tumor regression.
  • Surgical debulking and ablative therapies are options for select patients with liver metastases.
  • Systemic agents like chemotherapy and IFN-alpha have shown limited efficacy and significant toxicity.
  • Emerging therapies targeting VEGF and mTOR pathways demonstrate potential in advanced NETs.

Conclusions:

  • There is a significant unmet need for effective treatments for advanced neuroendocrine tumors.
  • Novel therapeutic strategies, including radiolabeled somatostatin analogs and targeted agents, offer promising avenues for future treatment.
  • Ongoing clinical trials are crucial to establish the role of these new agents in NET management.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...